Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

P1 Receptor Agonists/Antagonists in Clinical Trials - Potential Drug Candidates of the Future

Author(s): Pobitra Borah, Satyendra Deka, Raghu Prasad Mailavaram* and Pran Kishore Deb

Volume 25, Issue 26, 2019

Page: [2792 - 2807] Pages: 16

DOI: 10.2174/1381612825666190716111245

Price: $65

Abstract

Background: Adenosine mediates various physiological and pathological conditions by acting on its four P1 receptors (A1, A2A, A2B and A3 receptors). Omnipresence of P1 receptors and their activation, exert a wide range of biological activities. Thus, its modulation is implicated in various disorders like Parkinson’s disease, asthma, cardiovascular disorders, cancer etc. Hence these receptors have become an interesting target for the researchers to develop potential therapeutic agents. Number of molecules were designed and developed in the past few years and evaluated for their efficacy in various disease conditions.

Objective: The main objective is to provide an overview of new chemical entities which have crossed preclinical studies and reached clinical trials stage following their current status and future prospective.

Methods: In this review we discuss current status of the drug candidates which have undergone clinical trials and their prospects.

Results: Many chemical entities targeting various subtypes of P1 receptors are patented; twenty of them have crossed preclinical studies and reached clinical trials stage. Two of them viz adenosine and regadenoson are approved by the Food and Drug Administration.

Conclusion: This review is an attempt to highlight the current status, progress and probable future of P1 receptor ligands which are under clinical trials as promising novel therapeutic agents and the direction in which research should proceed with a view to come out with novel therapeutic agents.

Keywords: Adenosine, P1-receptors, agonists, antagonists, clinical-trials, regadenoson.

« Previous Next »
[1]
Fredholm BB. Adenosine receptors as drug targets. Exp Cell Res 2010; 316(8): 1284-8.
[http://dx.doi.org/10.1016/j.yexcr.2010.02.004] [PMID: 20153317]
[2]
Sousa JB, Fresco P, Diniz C, Goncalves J. Adenosine receptor ligands on cancer therapy: A review of patent literature. Recent Patents Anticancer Drug Discov 2018; 13(1): 40-69.
[http://dx.doi.org/10.2174/1574892812666171108115959] [PMID: 29119938]
[3]
Borea PA, Gessi S, Merighi S, Vincenzi F, Varani K. Pharmacology of adenosine receptors: The state of the art. Physiol Rev 2018; 98(3): 1591-625.
[http://dx.doi.org/10.1152/physrev.00049.2017] [PMID: 29848236]
[4]
Jacobson KA, Gao Z-G. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 2006; 5(3): 247-64.
[http://dx.doi.org/10.1038/nrd1983] [PMID: 16518376]
[5]
Müller CE, Jacobson KA. Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta 2011; 1808(5): 1290-308.
[http://dx.doi.org/10.1016/j.bbamem.2010.12.017] [PMID: 21185259]
[6]
Gessi S, Merighi S, Varani K, Borea PA. Adenosine receptors in health and disease. Adv Pharmacol 2011; 61: 41-75.
[http://dx.doi.org/10.1016/B978-0-12-385526-8.00002-3] [PMID: 21586355]
[7]
Chen J-F, Eltzschig HK, Fredholm BB. Adenosine receptors as drug targets--what are the challenges? Nat Rev Drug Discov 2013; 12(4): 265-86.
[http://dx.doi.org/10.1038/nrd3955] [PMID: 23535933]
[8]
Deb PK. Recent updates in the computer aided drug design strategies for the discovery of agonists and antagonists of adenosine receptors. Curr Pharm Des 2019; 25(7): 747-9.
[http://dx.doi.org/10.2174/1381612825999190515120510] [PMID: 31232230]
[9]
Samanta PN, Kar S, Leszczynski J. Recent advances of in-silico modeling of potent antagonists for the adenosine receptors. Curr Pharm Des 2019; 25(7): 750-73.
[http://dx.doi.org/10.2174/1381612825666190304123545] [PMID: 30836910]
[10]
Al-Shar’i NA, Al-Balas QA. Molecular dynamics simulations of adenosine receptors: Advances, applications and trends. Curr Pharm Des 2019; 25(7): 783-816.
[http://dx.doi.org/10.2174/1381612825666190304123414] [PMID: 30834825]
[11]
Mahmod Al-Qattan MN, Mordi MN, Nizam Mordi M. Molecular basis of modulating adenosine receptors activities. Curr Pharm Des 2019; 25(7): 817-31.
[http://dx.doi.org/10.2174/1381612825666190304122624] [PMID: 30834826]
[12]
Agrawal N, Chandrasekaran B, Al-Aboudi A. Recent advances in the in-silico structure-based and ligand-based approaches for the design and discovery of agonists and antagonists of A2A adenosine receptor. Curr Pharm Des 2019; 25(7): 774-82.
[http://dx.doi.org/10.2174/1381612825666190306162006] [PMID: 30848185]
[13]
Deb PK, Chandrasekaran B, Mailavaram R, Tekade RK, Jaber AMY. Molecular modeling approaches for the discovery of adenosine A2B receptor antagonists: Current status and future perspectives. Drug Discov Today 2019; 24(9): 1854-64.
[http://dx.doi.org/10.1016/j.drudis.2019.05.011] [PMID: 31103731]
[14]
Raghu Prasad M, Raghuram Rao A, Shanthan Rao P, Rajan KS, Meena S, Madhavi K. Synthesis and adenosine receptor binding studies of some novel triazolothienopyrimidines. Eur J Med Chem 2008; 43(3): 614-20.
[http://dx.doi.org/10.1016/j.ejmech.2007.05.001] [PMID: 17602796]
[15]
Deb PK, Mailavaram R, Chandrasekaran B, et al. Synthesis, adenosine receptor binding and molecular modelling studies of novel thieno[2,3-d]pyrimidine derivatives. Chem Biol Drug Des 2018; 91(4): 962-9.
[http://dx.doi.org/10.1111/cbdd.13155] [PMID: 29194979]
[16]
Pran Kishore D, Balakumar C, Raghuram Rao A, Roy PP, Roy K. QSAR of adenosine receptor antagonists: Exploring physicochemical requirements for binding of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives with human adenosine A(3) receptor subtype. Bioorg Med Chem Lett 2011; 21(2): 818-23.
[http://dx.doi.org/10.1016/j.bmcl.2010.11.094] [PMID: 21163647]
[17]
Balakumar C, Pran Kishore D, Sonja K, Raghuram Rao A, Raghuprasad M, Karl-Norbert K. Synthesis and adenosine receptors binding studies of new fluorinated analogues of pyrido[2,3-d]pyrimidines and quinazolines. Med Chem Res 2018; 27: 756-67.
[http://dx.doi.org/10.1007/s00044-017-2099-z]
[18]
Balakumar C, Pran Kishore D, Venkat Rao K, et al. Design, microwave-assisted synthesis and in silico docking studies of new 4H-pyrimido[2,1-b]-benzothiazole-2-arylamino-3-cyano-4-ones as possible adenosine A2B receptor antagonists. Indian J Chem 2012; 51B: 1105-13.http://nopr.niscair.res.in/handle/123456789/14508
[19]
Balakumar C, Pran Kishore D, Raghuram Rao A. Structure-based design and pharmacological study of fluorinated fused quinazolines as adenosine A2B receptor antagonists. JSM Chem 2017; 5: 1041-50.
[20]
Banda V, Chandrasekaran B, Köse M, et al. Synthesis of novel pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidine derivatives: Potent and selective adenosine A3 receptor antagonists. Arch Pharm 2013; 346(10): 699-707.
[http://dx.doi.org/10.1002/ardp.201300003] [PMID: 23996524]
[21]
Sirisha B, Narsaiah B, Yakaiah T, et al. Synthesis and theoretical studies on energetics of novel N- and O- perfluoroalkyl triazole tagged thienopyrimidines--their potential as adenosine receptor ligands. Eur J Med Chem 2010; 45(5): 1739-45.
[http://dx.doi.org/10.1016/j.ejmech.2009.12.075] [PMID: 20116907]
[22]
Praveen Kumar P, Ramesh A, Sri Chandana M, Raghu Prasad M, Prasad K. Protective effect of A2B receptor antagonist (TRP 1) on acetic acid induced ulcerative colitis in rats: In vitro, in vivo and in silico methods. IJPER 2018; 52: 101-9.
[http://dx.doi.org/10.5530/ijper.52.1.12]
[23]
Praveen Kumar P, Santhosh G, Sri Chandana M, Prasad K, Raghu Prasad M, Khasim S. Protective effect of A2B receptor antagonist (TRP 2) on acetic acid induced ulcerative colitis in rats: In vitro, in vivo and in silico methods. Indian J Physiol Pharmacol 2018; 62(3): 327-38.
[24]
Khasim S, Pran Kishore D, Raghu Prasad M, et al. 7-Amino-2-aryl/heteroaryl-5-oxo-5,8-dihydro[1,2,4]triazolo[1,5-a]pyridine-6-carbonitriles: Synthesis and adenosine receptor binding studies. Chem Biol Drug Des 2019; 94(2): 1568-73.
[http://dx.doi.org/10.1111/cbdd.13528]
[25]
Raghu Prasad M, Surya DSGPMVR, Shaik K, Pran Kishore D. Girija V. 7-Aryl-4-hydrazinyl-2,5,6-trialkyl-7H-heterofused[2,3- d]pyrimidine as potent antimycobacterial/antimalarial agent Indian Patent– Appl.No. 3594/CHE/2012, Publication No. 05/2015, Indian Patent 304256, 2018.
[26]
Habib AS, Minkowitz H, Osborn T, et al. Adenosine Study Group Phase 2, double-blind, placebo-controlled, dose-response trial of intravenous adenosine for perioperative analgesia. Anesthesiology 2008; 109(6): 1085-91.
[http://dx.doi.org/10.1097/ALN.0b013e31818db88c] [PMID: 19034105]
[27]
Ramakers BP, Riksen NP, van den Broek P, et al. Circulating adenosine increases during human experimental endotoxemia but blockade of its receptor does not influence the immune response and subsequent organ injury. Crit Care 2011; 15(1): R3.
[http://dx.doi.org/10.1186/cc9400] [PMID: 21211004]
[28]
Yan L, Burbiel JC, Maass A, Müller CE. Adenosine receptor agonists: From basic medicinal chemistry to clinical development. Expert Opin Emerg Drugs 2003; 8(2): 537-76.
[http://dx.doi.org/10.1517/14728214.8.2.537] [PMID: 14662005]
[29]
Linden J. Molecular approach to adenosine receptors: Receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol 2001; 41: 775-87.
[http://dx.doi.org/10.1146/annurev.pharmtox.41.1.775] [PMID: 11264476]
[30]
Schütte F, Burgdorf C, Richardt G, Kurz T. Adenosine A1 receptor-mediated inhibition of myocardial norepinephrine release involves neither phospholipase C nor protein kinase C but does involve adenylyl cyclase. Can J Physiol Pharmacol 2006; 84(5): 573-7.
[http://dx.doi.org/10.1139/y06-007] [PMID: 16902603]
[31]
Borea PA, Varani K, Vincenzi F, et al. The A3 adenosine receptor: History and perspectives. Pharmacol Rev 2015; 67(1): 74-102.
[http://dx.doi.org/10.1124/pr.113.008540] [PMID: 25387804]
[32]
Gao ZG, Jacobson KA. Emerging adenosine receptor agonists. Expert Opin Emerg Drugs 2007; 12(3): 479-92.
[http://dx.doi.org/10.1517/14728214.12.3.479] [PMID: 17874974]
[33]
Liebmann JM, Lee JK. Current therapeutic options and treatments in development for the management of primary open-angle glaucoma. Am J Manag Care 2017; 23(15): S279-92.
[PMID: 29164845]
[34]
Li G, Torrejon KY, Unser AM, et al. Trabodenoson, an adenosine mimetic with a1 receptor selectivity lowers intraocular pressure by increasing conventional outflow facility in mice. Invest Ophthalmol Vis Sci 2018; 59(1): 383-92.
[http://dx.doi.org/10.1167/iovs.17-23212] [PMID: 29346804]
[35]
Žiniauskaite A, Ragauskas S, Hakkarainen JJ, et al. Efficacy of trabodenoson in a mouse keratoconjunctivitis sicca (kcs) model for dry-eye syndrome. Invest Ophthalmol Vis Sci 2018; 59(7): 3088-93.
[http://dx.doi.org/10.1167/iovs.18-24432] [PMID: 30025146]
[36]
Myers JS, Sall KN, DuBiner H, et al. A dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of 2 and 4 weeks of twice-daily ocular trabodenoson in adults with ocular hypertension or primary open-angle glaucoma. J Ocul Pharmacol Ther 2016; 32(8): 555-62.
[http://dx.doi.org/10.1089/jop.2015.0148] [PMID: 27002298]
[37]
Albrecht-Küpper BE, Leineweber K, Nell PG. Partial adenosine A1 receptor agonists for cardiovascular therapies. Purinergic Signal 2012; 8(Suppl. 1): 91-9.
[http://dx.doi.org/10.1007/s11302-011-9274-3] [PMID: 22081230]
[38]
Greene SJ, Sabbah HN, Butler J, et al. Partial adenosine A1 receptor agonism: A potential new therapeutic strategy for heart failure. Heart Fail Rev 2016; 21(1): 95-102.
[http://dx.doi.org/10.1007/s10741-015-9522-7] [PMID: 26701329]
[39]
Fredholm BB, IJzerman AP, Jacobson KA, Klotz K-N, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001; 53(4): 527-52.
[PMID: 11734617]
[40]
Vallon V, Miracle C, Thomson S. Adenosine and kidney function: Potential implications in patients with heart failure. Eur J Heart Fail 2008; 10(2): 176-87.
[http://dx.doi.org/10.1016/j.ejheart.2008.01.010] [PMID: 18242127]
[41]
Tendera M, Gaszewska-Żurek E, Parma Z, et al. The new oral adenosine A1 receptor agonist capadenoson in male patients with stable angina. Clin Res Cardiol 2012; 101: 585-91. NCT00518921. Phase IIa efficacy and safety trial of capadenoson in patients with chronic stable angina, Available at clinicaltrials.gov/ct2/show/10.1007/s00392-012-0430-8
[42]
Sabbah HN, Gupta RC, Kohli S, et al. Chronic therapy with a partial adenosine A1 receptor agonist, improves left ventricular function and remodeling in dogs with advanced heart failure. Circ Heart Fail 2013; 6: 563-71.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.112.000208]
[43]
Baltos J-A, Vecchio EA, Harris MA, et al. Capadenoson, a clinically trialed partial adenosine A1 receptor agonist, can stimulate adenosine A2B receptor biased agonism. Biochem Pharmacol 2017; 135: 79-89.
[http://dx.doi.org/10.1016/j.bcp.2017.03.014] [PMID: 28344125]
[44]
Dinh W, Albrecht-Küpper B, Gheorghiade M, Voors AA, van der Laan M, Sabbah HN. Partial adenosine A1 agonist in heart failure. Springer International Publishing AG: Heart Failure 2016; 177- 203.
[45]
Voors AA, Düngen HD, Senni M, et al. Safety and tolerability of neladenoson bialanate, a novel oral partial adenosine A1 receptor agonist, in patients with chronic heart failure. J Clin Pharmacol 2017; 57(4): 440-51.
[http://dx.doi.org/10.1002/jcph.828] [PMID: 27624622]
[46]
Meibom D, Albrecht-Küpper B, Diedrichs N, et al. Neladenoson bialanate hydrochloride: A prodrug of a partial adenosine A1 receptor agonist for the chronic treatment of heart diseases. ChemMedChem 2017; 12(10): 728-37.
[http://dx.doi.org/10.1002/cmdc.201700151] [PMID: 28488817]
[47]
NCT02992288. A trial to study neladenoson bialanate over 20 weeks in patients with chronic heart failure with reduced ejection fraction (PANTHEON), Available at. clinicaltrials.gov/ct2/show/NCT02992288
[48]
NCT00376454. A multicenter, randomized, double-blind, placebocontrolled, parallel group study to evaluate the efficacy and tolerability of a 14 day treatment course of GW493838 50 mg compared to placebo in subjects with peripheral neuropathic pain. Clinical- Trials.gov. Available at clinicaltrials.gov/ct2/show/NCT00376454
[49]
Corino VD, Holmqvist F, Mainardi LT, Platonov PG. Beta-blockade and A1-adenosine receptor agonist effects on atrial fibrillatory rate and atrioventricular conduction in patients with atrial fibrillation. Europace 2014; 16(4): 587-94.
[http://dx.doi.org/10.1093/europace/eut251] [PMID: 23989533]
[50]
Voors AA, Dittrich HC, Massie BM, et al. Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: Results from PROTECT (placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function). J Am Coll Cardiol 2011; 57(19): 1899-907.
[http://dx.doi.org/10.1016/j.jacc.2010.11.057] [PMID: 21545947]
[51]
Cotter G, Dittrich HC, Weatherley BD, et al. Protect Steering Committee. Investigators, and Coordinators The PROTECT pilot study: A randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. J Card Fail 2008; 14(8): 631-40.
[http://dx.doi.org/10.1016/j.cardfail.2008.08.010] [PMID: 18926433]
[52]
Massie BM, O’Connor CM, Metra M, et al. PROTECT Investigators and Committees Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 2010; 363(15): 1419-28.
[http://dx.doi.org/10.1056/NEJMoa0912613] [PMID: 20925544]
[53]
Teerlink JR, Iragui VJ, Mohr JP, et al. The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: Findings from PROTECT. Drug Saf 2012; 35(3): 233-44.
[http://dx.doi.org/10.2165/11594680-000000000-00000] [PMID: 22339573]
[54]
Ter Maaten JM, Damman K, Hanberg JS, et al. Hypochloremia, diuretic resistance, and outcome in patients with acute heart failure -Clinical perspective. Circ Heart Fail 2016; 9(8)e003109
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.116.003109] [PMID: 27507112]
[55]
Matsue Y, van der Meer P, Damman K, et al. Blood urea nitrogen-to-creatinine ratio in the general population and in patients with acute heart failure. Heart 2017; 103(6): 407-13.
[http://dx.doi.org/10.1136/heartjnl-2016-310112] [PMID: 27658757]
[56]
Ter Maaten JM, Valente MA, Damman K, et al. Combining diuretic response and hemoconcentration to predict rehospitalization after admission for acute heart failure - Clinical perspective. Circ Heart Fail 2016; 9(6)e002845
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.115.002845] [PMID: 27266853]
[57]
O’connor CM, Fiuzat M, Lombardi C, et al. Impact of serial troponin release on outcomes in patients with acute heart failure - Clinical perspective: Analysis from the PROTECT pilot study. Circ Heart Fail 2011; 4: 724-32.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.111.961581] [PMID: 21900185]
[58]
Tromp J, Meyer S, Mentz RJ, et al. Acute heart failure in the young: Clinical characteristics and biomarker profiles. Int J Cardiol 2016; 221: 1067-72.
[http://dx.doi.org/10.1016/j.ijcard.2016.06.339] [PMID: 27448534]
[59]
Mitrovic V, Seferovic P, Dodic SS, et al. Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in chronic heart failure patients. J Card Fail 2008; 14: 798-9.
[http://dx.doi.org/10.1016/j.cardfail.2008.10.014]
[60]
Pang PS, Mehra M, Maggioni AP, et al. RENO-DEFEND Investigators Rationale, design, and results from RENO-DEFEND 1: a randomized, dose-finding study of the selective A1 adenosine antagonist SLV320 in patients hospitalized with acute heart failure. Am Heart J 2011; 161(6): 1012-23.e3.
[http://dx.doi.org/10.1016/j.ahj.2011.03.004] [PMID: 21641345]
[61]
NCT0263945. A study to assess the efficacy of a 5-day, 10- mg PBF-680 oral administration on late asthmatic responses (LAR) in mild to moderate asthmatic patients. Available at. clinicaltrials.gov/ct2/show/
[62]
NCT00745316. Oral Tonapofylline (BG9928) in patients with heart failure and renal insufficiency (POSEIDON) Available at clinicaltrials.gov/ct2/show/NCT00745316
[63]
Pleli T, Mondorf A, Ferreiros N, et al. Activation of adenylyl cyclase causes stimulation of adenosine receptors. Cell Physiol Biochem 2018; 45(6): 2516-28.
[http://dx.doi.org/10.1159/000488270] [PMID: 29587249]
[64]
Merighi S, Gessi S, Borea PA. Adenosine receptors: Structure, distribution, and signal transduction. In: The adenosine receptors, Borea PA, Varani K, Gessi A, Merighi S, Vincenzi F, Eds. 2018; 33-57.
[65]
Blum D, Chern Y, Domenici MR, et al. The role of adenosine tone and adenosine receptors in Huntington’s disease. J Caffeine Adenosine Res 2018; 8(2): 43-58.
[http://dx.doi.org/10.1089/caff.2018.0006] [PMID: 30023989]
[66]
Franco R, Navarro G. Adenosine A2A receptor antagonists in neurodegenerative diseases: Huge potential and huge challenges. Front Psychiatry 2018; 9: 68-72.
[http://dx.doi.org/10.3389/fpsyt.2018.00068] [PMID: 29593579]
[67]
Sousa JB, Diniz C. The adenosinergic system as a therapeutic target in the vasculature: New ligands and challenges. Molecules 2017; 22(5): 752-79.
[http://dx.doi.org/10.3390/molecules22050752] [PMID: 28481238]
[68]
Field JJ, Lin G, Okam MM, et al. Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson. Blood 2013; 121(17): 3329-34.
[http://dx.doi.org/10.1182/blood-2012-11-465963] [PMID: 23377438]
[69]
NCT00944970. Efficacy and safety study of binodenoson in assessing cardiac ischemia (VISION-305), Available at. clinicaltrials.gov/ct2/show/NCT00944970
[70]
NCT00318214. Safety and efficacy study of MRE0094 to treat large, single or multiple, chronic, neuropathic, diabetic foot ulcers. Safety and efficacy study of MRE0094 to treat large, single or multiple, chronic, neuropathic, diabetic foot ulcers. Available at clinicaltrials.gov/ct2/show/NCT00318214
[71]
NCT00452777. Efficacy and tolerability of novel A2A agonist in treatment of diabetic neuropathic pain. Available at clinicaltrials.gov/ct2/show/NCT00452777
[72]
LeWitt PA, Guttman M, Tetrud JW, et al. 6002-US-005 Study Group Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson’s disease: A double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol 2008; 63(3): 295-302.
[http://dx.doi.org/10.1002/ana.21315] [PMID: 18306243]
[73]
Hauser RA, Shulman LM, Trugman JM, et al. Study of istradefylline 6002-US-013 Study Group Study of istradefylline in patients with Parkinson’s disease on levodopa with motor fluctuations. Mov Disord 2008; 23(15): 2177-85.
[http://dx.doi.org/10.1002/mds.22095] [PMID: 18831530]
[74]
Kondo T, Mizuno Y. Japanese Istradefylline Study Group. A long-term study of istradefylline safety and efficacy in patients with Parkinson disease. Clin Neuropharmacol 2015; 38(2): 41-6.
[http://dx.doi.org/10.1097/WNF.0000000000000073] [PMID: 25768849]
[75]
Mukai M, Uchimura T, Zhang X, Greene D, Vergeire M, Cantillon M. Effects of rifampin on the pharmacokinetics of a single dose of istradefylline in healthy subjects. J Clin Pharmacol 2018; 58(2): 193-201.
[http://dx.doi.org/10.1002/jcph.1003] [PMID: 28881378]
[76]
Stocchi F, Rascol O, Hauser RA, et al. Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease. Neurology 2017; 88(23): 2198-206.
[http://dx.doi.org/10.1212/WNL.0000000000004003] [PMID: 28490648]
[77]
Hauser RA, Stocchi F, Rascol O, et al. Preladenant as an adjunctive therapy with levodopa in Parkinson disease: Two randomized clinical trials and lessons learned. JAMA Neurol 2015; 72(12): 1491-500.
[http://dx.doi.org/10.1001/jamaneurol.2015.2268] [PMID: 26523919]
[78]
Hattori N, Kikuchi M, Adachi N, Hewitt D, Huyck S, Saito T. Adjunctive preladenant: A placebo-controlled, dose-finding study in Japanese patients with Parkinson’s disease. Parkinsonism Relat Disord 2016; 32: 73-9.
[http://dx.doi.org/10.1016/j.parkreldis.2016.08.020] [PMID: 27632893]
[79]
Lane S, Green C, Steinberg J, et al. Cardiovascular and subjective effects of the novel adenosine A2A receptor antagonist SYN115 in cocaine dependent individuals. J Addict Res Ther 2012; S1: S1-S009.
[PMID: 22905331]
[80]
Moeller FG, Steinberg JL, Lane SD, et al. Increased orbitofrontal brain activation after administration of a selective adenosine A2A antagonist in cocaine dependent subjects. Front Psychiatry 2012; 3(44): 1-9.
[http://dx.doi.org/10.3389/fpsyt.2012.00044]
[81]
Sek K, Mølck C, Stewart GD, Kats L, Darcy PK, Beavis PA. Targeting adenosine receptor signaling in cancer immunotherapy. Int J Mol Sci 2018; 19(12): 3837-60.
[http://dx.doi.org/10.3390/ijms19123837] [PMID: 30513816]
[82]
Neumann CA, Levine K, Oesterreich S. Targeting adenosine receptor A2B in triple negative breast cancer. J Cancer Metastasis Treat 2018; 4: 13-20.
[http://dx.doi.org/10.20517/2394-4722.2017.60]
[83]
NCT03274479. PBF-1129 in Patients With NSCLC Available at. clinicaltrials.gov/ct2/show/NCT03274479
[84]
Varani K, Padovan M, Govoni M, Vincenzi F, Trotta F, Borea PA. The role of adenosine receptors in rheumatoid arthritis. Autoimmun Rev 2010; 10(2): 61-4.
[http://dx.doi.org/10.1016/j.autrev.2010.07.019] [PMID: 20691813]
[85]
Fishman P, Cohen S. The A3 adenosine receptor (A3AR): Therapeutic target and predictive biological marker in rheumatoid arthritis. Clin Rheumatol 2016; 35(9): 2359-62.
[http://dx.doi.org/10.1007/s10067-016-3202-4] [PMID: 26886128]
[86]
David M, Akerman L, Ziv M, et al. Treatment of plaque-type psoriasis with oral CF101: Data from an exploratory randomized phase 2 clinical trial. J Eur Acad Dermatol Venereol 2012; 26(3): 361-7.
[http://dx.doi.org/10.1111/j.1468-3083.2011.04078.x] [PMID: 21504485]
[87]
Avni I, Garzozi HJ, Barequet IS, et al. Treatment of dry eye syndrome with orally administered CF101: Data from a phase 2 clinical trial. Ophthalmology 2010; 117(7): 1287-93.
[http://dx.doi.org/10.1016/j.ophtha.2009.11.029] [PMID: 20304499]
[88]
Silverman MH, Strand V, Markovits D, et al. Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: Data from a phase II clinical trial. J Rheumatol 2008; 35(1): 41-8.
[PMID: 18050382]
[89]
Bar-Yehuda S, Stemmer SM, Madi L, et al. The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kappaB signal transduction pathways. Int J Oncol 2008; 33(2): 287-95.
[PMID: 18636149]
[90]
Stemmer SM, Benjaminov O, Medalia G, et al. CF102 for the treatment of hepatocellular carcinoma: A phase I/II, open-label, dose-escalation study. The Oncol 2013; 18: 25-6.
[91]
Fishman P. Inventor; Can-Fite Biopharma Ltd., Assignee. A3 adenosine receptor ligands for use in treatment of a sexual dysfunction. United States patent US 9549943B2, 2017.
[92]
NCT02639975. Randomized, Double blind, placebo controlled "First-in-human" study to assess the safety and tolerability of single ascending oral doses of PBF-677 (100 mg, 200 mg, 400 mg and 600 mg) in healthy young male volunteers. Available at clinicaltrials.gov/ct2/show/NCT02639975
[93]
Iskandrian AE, Bateman TM, Belardinelli L, et al. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol 2007; 14(5): 645-58.
[http://dx.doi.org/10.1016/j.nuclcard.2007.06.114] [PMID: 17826318]
[94]
Cerqueira MD, Nguyen P, Staehr P, Underwood SR, Iskandrian AE, Investigators AMT. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results. JACC Cardiovasc Imaging 2008; 1(3): 307-16.
[http://dx.doi.org/10.1016/j.jcmg.2008.02.003] [PMID: 19356442]
[95]
Aljaroudi W, Hermann D, Hage F, Heo J, Iskandrian AE. Safety of regadenoson in patients with end-stage renal disease. Am J Cardiol 2010; 105(1): 133-5.
[http://dx.doi.org/10.1016/j.amjcard.2009.08.663] [PMID: 20102905]
[96]
Thomas GS, Cullom SJ, Kitt TM, et al. The EXERRT trial: “EXErcise to Regadenoson in Recovery Trial”: A phase 3b, open-label, parallel group, randomized, multicenter study to assess regadenoson administration following an inadequate exercise stress test as compared to regadenoson without exercise for myocardial perfusion imaging using a SPECT protocol. J Nucl Cardiol 2017; 24(3): 788-802.
[http://dx.doi.org/10.1007/s12350-017-0813-3] [PMID: 28224449]

Rights & Permissions Print Cite
Article Metrics
37
3
© 2024 Bentham Science Publishers | Privacy Policy